Developer docs
API playgroundTry for free, no card

Search company profiles

Accelero Biostructures

Full company profile

uuid000mkif

Namestring
Accelero Biostructures
Legal namestring
Accelero Biostructures, Inc.
Websiteurl
accelerobio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Accelero Biostructures is a private contract research organization (CRO) founded in 2015 and based in the San Francisco Bay Area that provides structure-based drug discovery and structural biology services to pharmaceutical and biotechnology companies. The company is built around high-throughput protein X-ray crystallography, leveraging synchrotron-based data collection infrastructure at SLAC National Accelerator Laboratory and methodologies developed over more than 15 years within the Joint Center for Structural Genomics (JCSG) consortium. Its commercial offerings are organized around two proprietary platforms: ABS-Services℠, a unified gene-to-structure pipeline covering crystal screening, data collection, structure determination, refinement, SAXS, and analysis; and ABS-OneStep℠, a next-generation fragment-based drug discovery (FBDD) platform developed with NIH SBIR funding that resolves weak-affinity bottlenecks in conventional FBDD workflows by enabling single-step determination of fragment hits and their 3D binding-site structures.

The company's revenue model is professional services fee-for-service, with contracts negotiated directly through business development outreach and priced based on project scope. Its customer base is horizontally segmented across established and emerging pharmaceutical companies, biotechnology firms, and academic research institutions, with use cases spanning structure-based drug discovery, fragment-based screening, biologics characterization, and co-crystal structure determination. The company has produced more than 1,500 novel protein structures and over 300 peer-reviewed publications across its founders' careers, including work published in Nature, PNAS, JBC, and J Struct Biol. To date, the company has funded operations through NIH SBIR Phase I (September 2016) and Phase II (May 2019) non-dilutive grants, supplemented by service revenue, with no institutional venture capital identified in available sources.

Short descriptiontext

Accelero Biostructures is a San Francisco Bay Area CRO that provides protein X-ray crystallography-driven structure-based and fragment-based drug discovery services to pharmaceutical and biotechnology clients through its ABS-Services℠ and ABS-OneStep℠ platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structural biology services, protein crystallography, structure-based drug discovery, fragment-based drug discovery, contract research services
Industry1 code
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Structural Biology Contract Research Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Accelero Biostructures generates revenue by providing fee-for-service protein crystallography and structural biology research services to pharmaceutical companies, biotechnology firms, and academic institutions. Services include gene-to-structure determination, fragment-based drug discovery, co-crystal structure analysis, and custom structural biology projects on a contract basis.

accelerobio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Accelero Biostructures provides contract protein X-ray crystallography and structural biology services to pharmaceutical and biotechnology companies, anchored by two proprietary platforms: ABS-Services℠, a unified gene-to-structure pipeline offering high-throughput, high-quality, high-reliability structure determination, and ABS-OneStep℠, a next-generation fragment-based drug discovery platform that identifies fragment binding hits and 3D binding site structures in a single step. The company resolves bottlenecks across the entire gene-to-structure workflow, including crystal screening, X-ray data collection and processing, structure determination, refinement, analysis, SAXS, and co-crystal structure work for traditional and previously non-druggable targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SBDD overall has led to ~250 drugs in the market
+2 more records
Product overview1 text field

Accelero Biostructures offers a dual-platform portfolio centered on protein X-ray crystallography-driven drug discovery and structural biology. The core offering consists of ABS-Services℠, a comprehensive gene-to-structure protein crystallography pipeline providing high-throughput structure determination services for pharmaceutical and biotech clients; and ABS-OneStep℠, a next-generation fragment-based drug discovery platform that resolves bottlenecks in conventional FBDD approaches by enabling single-step determination of fragment binding hits and 3D binding site structures. Both platforms leverage synchrotron-based X-ray data collection and are designed to accelerate structure-based drug discovery for traditional and previously non-druggable targets.

Product and service2 records
1ABS-Services℠
CategoryStructural Biology Contract Research Services
Description

ABS-Services℠ is a unified pipeline of gene-to-structure protein X-ray crystallography solutions for the pharmaceutical and biotechnology industries, delivering high throughput, high quality, and high reliability structure determination. It supports structure-based drug discovery (SBDD) and protein engineering through crystal screening, X-ray data collection and processing, structure determination, refinement, analysis, SAXS, and complete gene-to-structure workflows, including co-crystal structures of protein-small molecule, protein-DNA/RNA, and protein-protein complexes.

2ABS-OneStep℠
CategoryFragment-Based Drug Discovery Services
Description

ABS-OneStep℠ is a next-generation fragment-based drug discovery (FBDD) platform that uses protein X-ray crystallography to provide an extremely sensitive and efficient single-step approach for determining fragment binding hits to orthosteric and allosteric sites and elucidating their 3D binding site structures. It resolves key bottlenecks in conventional FBDD approaches, including weak affinities for fragment binding, and is designed to expand FBDD to traditional and previously non-druggable targets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Strategic collaboration announced April 2026 to expand structural biology and drug discovery services. Leverages operations in the United States and Sweden to enhance workflow efficiency and broaden service reach for biopharma and biotech clients worldwide.

2Finsnobio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Partnership for X-ray crystallography drug discovery services announced July 2021. Finsnobio is a Swedish biotech company focused on fragment-based drug discovery using X-ray crystallography.

accelerobio.com
3XPose Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

Joint research collaboration announced December 2020 for the discovery and development of novel cancer therapies. Combines XPose Therapeutics' expertise with Accelero Biostructures' structural biology capabilities.

accelerobio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-07-01
Description

Partnership to develop pan-coronavirus inhibitors. The research was supported by NIH funding, demonstrating scientific merit recognized through competitive grant award.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Computational chemistry and structure-based drug discovery platform serving pharma and biotech. Overlaps with Accelero in SBDD enablement but operates as a broader software-plus-services platform with significantly larger scale and product economics.

TypeBroad incumbent
Description

Large global CRO offering a broad portfolio including structural biology, fragment-based discovery, and integrated drug discovery services. Competes with Accelero on the structural biology/FBDD service line but as part of a much wider contract research offering.

TypeDirect peer
Description

Germany-based structural biology CRO specializing in protein X-ray crystallography, fragment-based screening, and structure-based drug discovery. Direct competitor offering the same core service (gene-to-structure, co-crystallography) to the same pharma/biotech customer base.

TypeDirect peer
Description

Dutch structural biology CRO focused on protein crystallography and fragment-based lead discovery using X-ray and biophysical methods. Closely comparable service offering, delivery model, and target customer profile to Accelero.

5Astex Pharmaceuticals
TypeDirect peer
Description

Pioneer in fragment-based drug discovery using X-ray crystallography (now part of Taiho Pharmaceutical). Overlaps with Accelero's ABS-OneStep FBDD platform on technology and target client base, though Astex retains internal programs rather than being a pure CRO.

TypeBroad incumbent
Description

Large Chinese-headquartered CRO/CDMO with extensive drug discovery services including structural biology. Competes on breadth and scale rather than specialist crystallography depth, but overlaps on target customers and project types.

TypeDirect peer
Description

Sweden-based structural biology CRO offering protein crystallography and structure-based drug discovery services to pharma and biotech. Accelero's April 2026 strategic collaboration partner and the closest functional peer — overlapping service portfolio, target customer base, and technology stack.

TypeBroad incumbent
Description

Major global CRO with discovery and safety assessment services. Overlaps with Accelero in early-stage drug discovery support for pharma clients but does not specialize in protein crystallography to the same degree.

TypeDirect peer
Description

German structural biology CRO (part of the Ferring group) offering gene-to-structure, protein crystallography, and fragment screening services. Direct functional peer competing for the same pharma outsourcing budget.

TypeDirect peer
Description

UK-based fragment-based drug discovery company (now part of HitGen) using structure-based approaches including X-ray crystallography. Comparable technology overlap in FBDD and structure-based design serving pharma collaborators.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accelero Biostructures

Structural Biology Contract Research Servicesaccelerobio.com

Accelero Biostructures is a San Francisco Bay Area CRO that provides protein X-ray crystallography-driven structure-based and fragment-based drug discovery services to pharmaceutical and biotechnology clients through its ABS-Services℠ and ABS-OneStep℠ platforms.

What Accelero Biostructures does

Accelero Biostructures is a private contract research organization (CRO) founded in 2015 and based in the San Francisco Bay Area that provides structure-based drug discovery and structural biology services to pharmaceutical and biotechnology companies. The company is built around high-throughput protein X-ray crystallography, leveraging synchrotron-based data collection infrastructure at SLAC National Accelerator Laboratory and methodologies developed over more than 15 years within the Joint Center for Structural Genomics (JCSG) consortium. Its commercial offerings are organized around two proprietary platforms: ABS-Services℠, a unified gene-to-structure pipeline covering crystal screening, data collection, structure determination, refinement, SAXS, and analysis; and ABS-OneStep℠, a next-generation fragment-based drug discovery (FBDD) platform developed with NIH SBIR funding that resolves weak-affinity bottlenecks in conventional FBDD workflows by enabling single-step determination of fragment hits and their 3D binding-site structures.

The company's revenue model is professional services fee-for-service, with contracts negotiated directly through business development outreach and priced based on project scope. Its customer base is horizontally segmented across established and emerging pharmaceutical companies, biotechnology firms, and academic research institutions, with use cases spanning structure-based drug discovery, fragment-based screening, biologics characterization, and co-crystal structure determination. The company has produced more than 1,500 novel protein structures and over 300 peer-reviewed publications across its founders' careers, including work published in Nature, PNAS, JBC, and J Struct Biol. To date, the company has funded operations through NIH SBIR Phase I (September 2016) and Phase II (May 2019) non-dilutive grants, supplemented by service revenue, with no institutional venture capital identified in available sources.

Accelero Biostructures firmographics

Firmographics
Name
Accelero Biostructures
Legal name
Accelero Biostructures, Inc.
Website
https://accelerobio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Accelero Biostructures is a San Francisco Bay Area CRO that provides protein X-ray crystallography-driven structure-based and fragment-based drug discovery services to pharmaceutical and biotechnology clients through its ABS-Services℠ and ABS-OneStep℠ platforms.
Ownership category
akta.pro rank

Accelero Biostructures industry classification

Industry
Product category
Structural Biology Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • Structural biology services
  • Protein crystallography
  • Structure-based drug discovery
  • Fragment-based drug discovery
  • Contract research services

Where Accelero Biostructures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Accelero Biostructures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Contract Research Services: Accelero Biostructures generates revenue by providing fee-for-service protein crystallography and structural biology research services to pharmaceutical companies, biotechnology firms, and academic institutions. Services include gene-to-structure determination, fragment-based drug discovery, co-crystal structure analysis, and custom structural biology projects on a contract basis.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Accelero Biostructures product offering

Product offering

Core offering

Accelero Biostructures provides contract protein X-ray crystallography and structural biology services to pharmaceutical and biotechnology companies, anchored by two proprietary platforms: ABS-Services℠, a unified gene-to-structure pipeline offering high-throughput, high-quality, high-reliability structure determination, and ABS-OneStep℠, a next-generation fragment-based drug discovery platform that identifies fragment binding hits and 3D binding site structures in a single step. The company resolves bottlenecks across the entire gene-to-structure workflow, including crystal screening, X-ray data collection and processing, structure determination, refinement, analysis, SAXS, and co-crystal structure work for traditional and previously non-druggable targets.

Product overview

Accelero Biostructures offers a dual-platform portfolio centered on protein X-ray crystallography-driven drug discovery and structural biology. The core offering consists of ABS-Services℠, a comprehensive gene-to-structure protein crystallography pipeline providing high-throughput structure determination services for pharmaceutical and biotech clients; and ABS-OneStep℠, a next-generation fragment-based drug discovery platform that resolves bottlenecks in conventional FBDD approaches by enabling single-step determination of fragment binding hits and 3D binding site structures. Both platforms leverage synchrotron-based X-ray data collection and are designed to accelerate structure-based drug discovery for traditional and previously non-druggable targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABS-Services℠ ABS-Services℠ is a unified pipeline of gene-to-structure protein X-ray crystallography solutions for the pharmaceutical and biotechnology industries, delivering high throughput, high quality, and high reliability structure determination. It supports structure-based drug discovery (SBDD) and protein engineering through crystal screening, X-ray data collection and processing, structure determination, refinement, analysis, SAXS, and complete gene-to-structure workflows, including co-crystal structures of protein-small molecule, protein-DNA/RNA, and protein-protein complexes.
  • ABS-OneStep℠ ABS-OneStep℠ is a next-generation fragment-based drug discovery (FBDD) platform that uses protein X-ray crystallography to provide an extremely sensitive and efficient single-step approach for determining fragment binding hits to orthosteric and allosteric sites and elucidating their 3D binding site structures. It resolves key bottlenecks in conventional FBDD approaches, including weak affinities for fragment binding, and is designed to expand FBDD to traditional and previously non-druggable targets.

Quantifiable outcome

  • SBDD overall has led to ~250 drugs in the market
  • +2 more outcomes

Companies that use Accelero Biostructures

Customer profile

Segments3 records

Ideal customer profiles3 records

Accelero Biostructures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Accelero Biostructures partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • SARomics BiostructurescoreStrategic or Co-development Partner · 2 April 2026Strategic collaboration announced April 2026 to expand structural biology and drug discovery services. Leverages operations in the United States and Sweden to enhance workflow efficiency and broaden service reach for biopharma and biotech clients worldwide.
  • FinsnobiocoreStrategic or Co-development Partner · 1 July 2021Partnership for X-ray crystallography drug discovery services announced July 2021. Finsnobio is a Swedish biotech company focused on fragment-based drug discovery using X-ray crystallography.
  • XPose TherapeuticscoreStrategic or Co-development Partner · 1 December 2020Joint research collaboration announced December 2020 for the discovery and development of novel cancer therapies. Combines XPose Therapeutics' expertise with Accelero Biostructures' structural biology capabilities.
  • Mid-Atlantic BioTherapeuticsminorStrategic or Co-development Partner · 1 July 2020Partnership to develop pan-coronavirus inhibitors. The research was supported by NIH funding, demonstrating scientific merit recognized through competitive grant award.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Accelero Biostructures competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Computational chemistry and structure-based drug discovery platform serving pharma and biotech. Overlaps with Accelero in SBDD enablement but operates as a broader software-plus-services platform with significantly larger scale and product economics.
  • Evotec: Large global CRO offering a broad portfolio including structural biology, fragment-based discovery, and integrated drug discovery services. Competes with Accelero on the structural biology/FBDD service line but as part of a much wider contract research offering.
  • WuXi AppTec: Large Chinese-headquartered CRO/CDMO with extensive drug discovery services including structural biology. Competes on breadth and scale rather than specialist crystallography depth, but overlaps on target customers and project types.
  • Charles River Laboratories: Major global CRO with discovery and safety assessment services. Overlaps with Accelero in early-stage drug discovery support for pharma clients but does not specialize in protein crystallography to the same degree.

Direct peers

  • Proteros: Germany-based structural biology CRO specializing in protein X-ray crystallography, fragment-based screening, and structure-based drug discovery. Direct competitor offering the same core service (gene-to-structure, co-crystallography) to the same pharma/biotech customer base.
  • ZoBio: Dutch structural biology CRO focused on protein crystallography and fragment-based lead discovery using X-ray and biophysical methods. Closely comparable service offering, delivery model, and target customer profile to Accelero.
  • Astex Pharmaceuticals: Pioneer in fragment-based drug discovery using X-ray crystallography (now part of Taiho Pharmaceutical). Overlaps with Accelero's ABS-OneStep FBDD platform on technology and target client base, though Astex retains internal programs rather than being a pure CRO.
  • SARomics Biostructures: Sweden-based structural biology CRO offering protein crystallography and structure-based drug discovery services to pharma and biotech. Accelero's April 2026 strategic collaboration partner and the closest functional peer — overlapping service portfolio, target customer base, and technology stack.
  • Crelux: German structural biology CRO (part of the Ferring group) offering gene-to-structure, protein crystallography, and fragment screening services. Direct functional peer competing for the same pharma outsourcing budget.
  • Vernalis: UK-based fragment-based drug discovery company (now part of HitGen) using structure-based approaches including X-ray crystallography. Comparable technology overlap in FBDD and structure-based design serving pharma collaborators.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Accelero Biostructures social profiles

Digital presence

Accelero Biostructures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accelero Biostructures leadership team

Management profile

Number of profiles

Profiles3 records

Accelero Biostructures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accelero Biostructures M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelero Biostructures

What does Accelero Biostructures do?

Accelero Biostructures provides contract protein X-ray crystallography and structural biology services to pharmaceutical and biotechnology companies, anchored by two proprietary platforms: ABS-Services℠, a unified gene-to-structure pipeline offering high-throughput, high-quality, high-reliability structure determination, and ABS-OneStep℠, a next-generation fragment-based drug discovery platform that identifies fragment binding hits and 3D binding site structures in a single step. The company resolves bottlenecks across the entire gene-to-structure workflow, including crystal screening, X-ray data collection and processing, structure determination, refinement, analysis, SAXS, and co-crystal structure work for traditional and previously non-druggable targets.

Is Accelero Biostructures a public or private company?

Accelero Biostructures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Accelero Biostructures founded?

Accelero Biostructures was founded in 2015. It employs 1 to 10 people.

Where is Accelero Biostructures based?

Accelero Biostructures is headquartered in San Francisco, United States, in the North America region.

How does Accelero Biostructures make money?

One revenue line is on record: contract Research Services.

Who are Accelero Biostructures's main competitors?

Broad incumbents on record are Schrödinger, Evotec, WuXi AppTec and Charles River Laboratories. Direct peers are Proteros, ZoBio, Astex Pharmaceuticals, SARomics Biostructures, Crelux and Vernalis.

Does Accelero Biostructures have an API?

No public API is recorded for Accelero Biostructures.

What industry is Accelero Biostructures in?

Accelero Biostructures's product category is Structural Biology Contract Research Services. Its primary akta.pro industry code is HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals